Multiple Sclerosis - Pipeline Review, H1 2012

Multiple Sclerosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H1 2012', provides an overview of the Multiple Sclerosis therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. 'Multiple Sclerosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Multiple Sclerosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Multiple Sclerosis Therapeutic Products under Development, Key Players in Multiple Sclerosis Therapeutics, Multiple Sclerosis Pipeline Overview, Multiple Sclerosis Pipeline, Multiple Sclerosis Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Multiple Sclerosis Overview
Therapeutics Development
An Overview of Pipeline Products for Multiple Sclerosis
Multiple Sclerosis Therapeutics under Development by Companies
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Multiple Sclerosis Therapeutics – Products under Development by Companies
Multiple Sclerosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Multiple Sclerosis Therapeutics Development
Alcon, Inc.
Genzyme Corporation
Baxter International Inc.
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Sanofi-Aventis
Eli Lilly and Company
Athersys, Inc.
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Micromet, Inc.
XenoPort, Inc.
Apitope International NV
Teijin Pharma Limited
Novartis AG
Acorda Therapeutics, Inc.
Actelion Ltd
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Elan Corporation, plc
Glenmark Pharmaceuticals Ltd.
Mitsubishi Tanabe Pharma Corporation
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Genmab A/S
AutoImmune Inc.
Celgene Corporation
Vernalis plc
Geron Corporation
SRI International
Merck KGaA
4SC AG
Addex Pharmaceuticals
Evotec Aktiengesellschaft
Genesis Research and Development Corporation Ltd.
Hemispherx Biopharma, Inc.
Hollis-Eden Pharmaceuticals, Inc.
IntelGenx Technologies Corp.
Antisense Therapeutics Limited
AVANIR Pharmaceuticals
Karo Bio
Almirall, S.A.
Lpath, Inc.
Medivir AB
BioMS Medical Corp.
Bionomics Limited
PROLOR Biotech, Inc.
MultiCell Technologies, Inc.
Nutra Pharma Corporation
Opexa Therapeutics, Inc.
Compugen Ltd.
Critical Outcome Technologies Inc.
Accentia Biopharmaceuticals, Inc.
Zenotech Laboratories Limited
RegeneRx Biopharmaceuticals, Inc.
Tolerx, Inc.
ProMetic Life Sciences Inc.
MorphoSys AG
Cytos Biotechnology AG
Pluristem Therapeutics Inc.
Galapagos NV
Synta Pharmaceuticals Corp.
Sareum Holdings plc
Santhera Pharmaceuticals Holding AG
Shenzhen Beike Biotechnology Co., Ltd.
Stem Cell Therapeutics Corp.
InDex Pharmaceuticals AB
Digna Biotech, S.L.
Avanti Therapeutics
Axxam SpA
Bayhill Therapeutics, Inc.
Probiodrug AG
Phenex Pharmaceuticals AG
Trophos SA
Artielle ImmunoTherapeutics, Inc.
InterMed Discovery GmbH
Affectis Pharmaceuticals AG
ProtAffin Biotechnologie AG
Circassia Holdings Ltd.
Allozyne, Inc.
Coronado Biosciences, Inc.
Clinquest Group, B.V.
Q Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Vaccinex, Inc.
Peptimmune, Inc.
Innate Therapeutics Limited
Kineta, Inc.
Deciphera Pharmaceuticals, LLC
Xention Limited
Txcell SA
Theraclone Sciences, Inc.
Virobay Inc.
Bolder Biotechnology, Inc.
Aegis Therapeutics, LLC
Xencor, Inc.
Adeona Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
ChemoCentryx, Inc.
Biovista Inc.
CBio Limited
SanBio, Inc.
AB Science
Provid Pharmaceuticals, Inc.
KYORIN Pharmaceutical Co., Ltd.
OncoImmune, Inc.
Hy BioPharma Inc.
PharmaEssentia Corporation
KAHR medical Ltd.
M's Science Corporation
Ferring Pharmaceuticals, Inc.
Pharnext SAS
Cellceutix Pharmaceuticals, Inc.
Amplimmune, Inc.
Lycera Corp.
Vakzine Projekt Management GmbH
Receptos, Inc.
Cellmid Ltd
Immune Technologies and Medicine
FINEPHARM SP. Z O.O.
Multiple Sclerosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aubagio - Drug Profile
Aubagio - Drug Profile
E2007 - Drug Profile
Laquinimod - Drug Profile
RG1594 - Drug Profile
BAF312 - Drug Profile
Campath - Drug Profile
LY2127399 - Drug Profile
Dirucotide - Drug Profile
Daclizumab - Drug Profile
Firategrast - Drug Profile
ELND002 - Drug Profile
Arzerra - Drug Profile
AVP-923 - Drug Profile
AIN457 - Drug Profile
Ponesimod - Drug Profile
BIIB017 - Drug Profile
Tysabri - Drug Profile
Stelara - Drug Profile
RPI-78M - Drug Profile
ATX-MS-1467 - Drug Profile
MN-166 - Drug Profile
Myloral - Drug Profile
Alferon N Injection - Drug Profile
RGN-352 - Drug Profile
MCT-125 - Drug Profile
Trimesta - Drug Profile
CYREVIA - Drug Profile
Tovaxin - Drug Profile
BHT-3009 - Drug Profile
GRC 4039 - Drug Profile
F991 Peptide - Drug Profile
Olesoxime - Drug Profile
ATL1102 - Drug Profile
Nanocort - Drug Profile
Autologous Bone Marrow Mesenchymal Stem Cells Transplantation - Drug Profile
ONO-4641 - Drug Profile
Simvastatin - Drug Profile
XToll - Drug Profile
NU100 - Drug Profile
Marijuana - Drug Profile
Avonex + Cellcept - Drug Profile
Minocycline - Drug Profile
CCX140 - Drug Profile
BG-12 - Drug Profile
BCG Vaccine - Drug Profile
Botulinum Toxin Type A - Drug Profile
SentoClone - Drug Profile
AB1010 - Drug Profile
Catena - Drug Profile
Ocrelizumab + Methylprednisolone - Drug Profile
Duloxetine - Drug Profile
Ginkgo Biloba - Drug Profile
L-Carnitine - Drug Profile
MIS416 - Drug Profile
Avonex + Riluzole - Drug Profile
Interferon-Beta + Multiferon - Drug Profile
Interferon Beta-1b - Drug Profile
Glatiramer Acetate - Drug Profile
Interferon Beta 1-a - Drug Profile
Autologous Mesenchymal Stem Cells - Drug Profile
Lutenyl + Dermestril Septem - Drug Profile
Tysabri Subcutaneous - Drug Profile
Ampydin - Drug Profile
Alemtuzumab - Drug Profile
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Venilon - Drug Profile
Teriflunomide + Glatiramer Acetate - Drug Profile
NT-KO-003 - Drug Profile
NeuroVax - Drug Profile
Trichuris Suis Ova - Drug Profile
Peptide-Coupled Peripheral Blood Mononuclear Cells - Drug Profile
Multiple Sclerosis Therapeutics – Drug Profile Updates
Multiple Sclerosis Therapeutics – Discontinued Products
Multiple Sclerosis Therapeutics - Dormant Products
Multiple Sclerosis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Multiple Sclerosis, H1 2012
Products under Development for Multiple Sclerosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Development by Companies, H1 2012 (Contd..8)
Number of Products under Development by Companies, H1 2012 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Development by Companies, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Alcon, Inc., H1 2012
Genzyme Corporation, H1 2012
Baxter International Inc., H1 2012
Johnson & Johnson, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Biogen Idec Inc., H1 2012
Sanofi-Aventis, H1 2012
Eli Lilly and Company, H1 2012
Athersys, Inc., H1 2012
GlaxoSmithKline plc, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Micromet, Inc., H1 2012
XenoPort, Inc., H1 2012
Apitope International NV, H1 2012
Teijin Pharma Limited, H1 2012
Novartis AG, H1 2012
Acorda Therapeutics, Inc., H1 2012
Actelion Ltd, H1 2012
Astellas Pharma Inc., H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Eisai Co., Ltd., H1 2012
Elan Corporation, plc, H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Mitsubishi Tanabe Pharma Corporation, H1 2012
Rigel Pharmaceuticals, Inc., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Genmab A/S, H1 2012
AutoImmune Inc., H1 2012
Celgene Corporation, H1 2012
Vernalis plc, H1 2012
Geron Corporation, H1 2012
SRI International, H1 2012
Merck KGaA, H1 2012
4SC AG, H1 2012
Addex Pharmaceuticals, H1 2012
Evotec Aktiengesellschaft, H1 2012
Genesis Research and Development Corporation Ltd., H1 2012
Hemispherx Biopharma, Inc., H1 2012
Hollis-Eden Pharmaceuticals, Inc., H1 2012
IntelGenx Technologies Corp., H1 2012
Antisense Therapeutics Limited, H1 2012
AVANIR Pharmaceuticals, H1 2012
Karo Bio, H1 2012
Almirall, S.A., H1 2012
Lpath, Inc., H1 2012
Medivir AB, H1 2012
BioMS Medical Corp., H1 2012
Bionomics Limited, H1 2012
PROLOR Biotech, Inc., H1 2012
MultiCell Technologies, Inc., H1 2012
Nutra Pharma Corporation, H1 2012
Opexa Therapeutics, Inc., H1 2012
Compugen Ltd., H1 2012
Critical Outcome Technologies Inc., H1 2012
Accentia Biopharmaceuticals, Inc., H1 2012
Zenotech Laboratories Limited, H1 2012
RegeneRx Biopharmaceuticals, Inc., H1 2012
Tolerx, Inc., H1 2012
ProMetic Life Sciences Inc., H1 2012
MorphoSys AG, H1 2012
Cytos Biotechnology AG, H1 2012
Pluristem Therapeutics Inc., H1 2012
Galapagos NV, H1 2012
Synta Pharmaceuticals Corp., H1 2012
Sareum Holdings plc, H1 2012
Santhera Pharmaceuticals Holding AG, H1 2012
Shenzhen Beike Biotechnology Co., Ltd., H1 2012
Stem Cell Therapeutics Corp., H1 2012
InDex Pharmaceuticals AB, H1 2012
Digna Biotech, S.L., H1 2012
Avanti Therapeutics, H1 2012
Axxam SpA, H1 2012
Bayhill Therapeutics, Inc., H1 2012
Probiodrug AG, H1 2012
Phenex Pharmaceuticals AG, H1 2012
Trophos SA, H1 2012
Artielle ImmunoTherapeutics, Inc., H1 2012
InterMed Discovery GmbH, H1 2012
Affectis Pharmaceuticals AG, H1 2012
ProtAffin Biotechnologie AG, H1 2012
Circassia Holdings Ltd., H1 2012
Allozyne, Inc., H1 2012
Coronado Biosciences, Inc., H1 2012
Clinquest Group, B.V., H1 2012
Q Therapeutics, Inc., H1 2012
Catabasis Pharmaceuticals, Inc., H1 2012
Vaccinex, Inc., H1 2012
Peptimmune, Inc., H1 2012
Innate Therapeutics Limited, H1 2012
Kineta, Inc., H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
Xention Limited, H1 2012
Txcell SA, H1 2012
Theraclone Sciences, Inc., H1 2012
Virobay Inc., H1 2012
Bolder Biotechnology, Inc., H1 2012
Aegis Therapeutics, LLC, H1 2012
Xencor, Inc., H1 2012
Adeona Pharmaceuticals, Inc., H1 2012
Trillium Therapeutics Inc., H1 2012
ChemoCentryx, Inc., H1 2012
Biovista Inc., H1 2012
CBio Limited, H1 2012
SanBio, Inc., H1 2012
AB Science, H1 2012
Provid Pharmaceuticals, Inc., H1 2012
KYORIN Pharmaceutical Co., Ltd., H1 2012
OncoImmune, Inc., H1 2012
Hy BioPharma Inc., H1 2012
PharmaEssentia Corporation, H1 2012
KAHR medical Ltd., H1 2012
M's Science Corporation, H1 2012
Ferring Pharmaceuticals, Inc., H1 2012
Pharnext SAS, H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Amplimmune, Inc., H1 2012
Lycera Corp., H1 2012
Vakzine Projekt Management GmbH, H1 2012
Receptos, Inc., H1 2012
Cellmid Ltd, H1 2012
Immune Technologies and Medicine, H1 2012
FINEPHARM SP. Z O.O., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Multiple Sclerosis Therapeutics – Drug Profile Updates
Multiple Sclerosis Therapeutics – Discontinued Products
Multiple Sclerosis Therapeutics – Discontinued Products (Contd..1)
Multiple Sclerosis Therapeutics – Discontinued Products (Contd..2)
Multiple Sclerosis Therapeutics – Dormant Products
Multiple Sclerosis Therapeutics – Dormant Products (Contd..1)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..2)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..3)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..4)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..5)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..6)
Multiple Sclerosis Therapeutics – Dormant Products (Contd..7)

List of Figures
Number of Products under Development for Multiple Sclerosis, H1 2012
Products under Development for Multiple Sclerosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012